CD64 (biology)
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Fc fragment of IgG, high affinity Ia, receptor (CD64)
| |
| Identifiers | |
| Symbol | FCGR1A |
| Entrez | 2209 |
| HUGO | 3613 |
| OMIM | 146760 |
| RefSeq | NM_000566 |
| UniProt | P12314 |
| Other data | |
| Locus | Chr. 1 q21.2-21.3 |
| Fc fragment of IgG, high affinity Ib, receptor (CD64)
| |
| Identifiers | |
| Symbol | FCGR1B |
| Entrez | 2210 |
| HUGO | 3614 |
| OMIM | 601502 |
| RefSeq | NM_001004340 |
| UniProt | Q92637 |
| Other data | |
| Locus | Chr. 1 p11.2 |
| Fc fragment of IgG, high affinity Ic, receptor (CD64)
| |
| Identifiers | |
| Symbol | FCGR1C |
| Entrez | 2211 |
| HUGO | 3615 |
| OMIM | 601503 |
| RefSeq | XM_001133198 |
| Other data | |
| Locus | Chr. 1 q21.1 |
CD64 is a type of integral membrane glycoprotein known as an Fc receptor that binds monomeric IgG-type antibodies with high affinity.[1] It is more commonly known as Fc-gamma receptor 1 (FcγRI). After binding IgG, CD64 interacts with an accessory chain known as the common γ chain (γ chain), which possesses an ITAM motif that is necessary for triggering cellular activation.[2]
Structurally CD64 is composed of a signal peptide that allows its transport to the surface of a cell, three extracellular immunoglobulin domains of the C2-type that it uses to bind antibody, a hydrophobic transmembrane domain, and a short cytoplasmic tail.[3]
CD64 is constitutively found on only macrophages and monocytes, but treatment of polymorphonuclear leukocytes with cytokines like IFNγ and G-CSF can induce CD64 expression on these cells.[4][5]
There are three distinct (but highly similar) genes in humans for CD64 called FcγRIA (CD64A), FcγRIB (CD64B), and FcγRIC (CD64C) that are located on chromosome 1.[6] These three genes produce six different mRNA transcripts ; two from CD64A, three from CD64B, and one from CD64C; by alternate splicing of the genes.[7]
References
- ↑ Hulett M, Hogarth P (1998). "The second and third extracellular domains of FcgammaRI (CD64) confer the unique high affinity binding of IgG2a". Mol Immunol 35 (14-15): 989-96. PMID 9881694.
- ↑ Nimmerjahn F, Ravetch J (2006). "Fcgamma receptors: old friends and new family members". Immunity 24 (1): 19-28. PMID 16413920.
- ↑ Ernst L, Duchemin A, Miller K, Anderson C (1998). "Molecular characterization of six variant Fcgamma receptor class I (CD64) transcripts". Mol Immunol 35 (14-15): 943-54. PMID 9881690.
- ↑ Perussia B, Dayton E, Lazarus R, Fanning V, Trinchieri G (1983). "Immune interferon induces the receptor for monomeric IgG1 on human monocytic and myeloid cells". J Exp Med 158 (4): 1092-113. PMID 6225822.
- ↑ Repp R, Valerius T, Sendler A, Gramatzki M, Iro H, Kalden J, Platzer E (1991). "Neutrophils express the high affinity receptor for IgG (Fc gamma RI, CD64) after in vivo application of recombinant human granulocyte colony-stimulating factor". Blood 78 (4): 885-9. PMID 1714327.
- ↑ Ernst L, van de Winkel J, Chiu I, Anderson C (1992). "Three genes for the human high affinity Fc receptor for IgG (Fc gamma RI) encode four distinct transcription products". J Biol Chem 267 (22): 15692-700. PMID 1379234.
- ↑ Ernst L, Duchemin A, Miller K, Anderson C (1998). "Molecular characterization of six variant Fcgamma receptor class I (CD64) transcripts". Mol Immunol 35 (14-15): 943-54. PMID 9881690.
External links
Proteins: clusters of differentiation (see also list of human clusters of differentiation) | |
|---|---|
| 1-50 | CD1 (CD1a-c, CD1d) - CD2 - CD3 - CD4 - CD5 - CD8 - CD9 - CD10 - CD11 (CD11a, CD11b, CD11c) - CD13 - CD14 - CD15 - CD16 - CD18 - CD19 - CD20 - CD21 - CD22 - CD23 - CD24 - CD25 - CD26 - CD27 - CD28 - CD29 - CD30 - CD31 - CD32 - CD33 - CD34 - CD35 - CD36 - CD37 -CD38 - CD40 - CD43 - CD44 - CD45 - CD46 - CD49 (CD49a, CD49b, CD49c, CD49d) |
| 51-100 | CD52 - CD53 - CD54 - CD55 - CD56 - CD58 - CD59 - CD61 - CD62 (CD62E, CD62L, CD62P) - CD63 - CD64 - CD66e - CD68 - CD70 - CD71 - CD72 - CD79 - CD80 - CD81 - CD82 - CD83 - CD86 - CD88 - CD89 - CD90 - CD94 - CD95 - CD97 - CD98 |
| 101-350 | CD103 - CD106 - CD114 - CD116 - CD117 - CD118 - CD120 - CD122 - CD130 - CD131 - CD132 - CD133 - CD134 - CD135 - CD137 - CD138 - CD141 - CD142 - CD143 - CD146 - CD147 - CD151 - CD152 - CD153 - CD154 - CD155 - CD162 - CD164 - CD169 - CD184 - CD206 - CD209 - CD257 - CD278 - CD281 - CD282 - CD283 - CD304 |
Transmembrane receptors: immune receptors | |
|---|---|
| Cytokine receptor | Type I: interleukin (IL-2, IL-3) - CSF (Erythropoietin, GM-CSF, G-CSF) - Glycoprotein 130/Oncostatin M - Leukemia inhibitory factor - common subunits (Common gamma chain, CSF2RB) Type II: interleukin (IL22RA2) - interferon (IFNAR, IFNGR) |
| Pattern recognition/Toll-like | TLR 1 - TLR 2 - TLR 3 - TLR 4 - TLR 5 - TLR 6 - TLR 7 - TLR 8 - TLR 9 - TLR 10 |
| Fc receptor | ε (FcεRI, FcεRII) - γ (FcγRI, FcγRII, FcγRIII) - α/μ (FcαRI, Fcα/μR) - Neonatal |
| Lymphocyte homing receptor | CD44 - L-selectin - VLA-4 - LFA-1 |
| other | Antigen receptor (B-cell, T cell) - Complement - Formyl peptide - Immunophilins - Integrin - Killer-cell immunoglobulin-like - Scavenger |
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .

